Check out this article by Foley & Lardner in response to an unprecedented move by the U.S. Food and Drug Administration (FDA or Agency) detailing a warning letter sent to Amazon.com, Inc. (Amazon), a fulfillment house, with respect to distributing over-the-counter (OTC) drug products that are in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act).
This article provides key considerations for telehealth providers in mapping out how to deliver care on a multi-state basis in light of the Dobbs decision and related state legislation.
Check out this whitepaper developed by Foley & Lardner LLP to learn more about the top twelve trends in the digital assets space.
Check out this resource developed by Foley & Lardner LLP that focuses on the top seventeen trends for the health & life sciences sector in 2022.
On July 7, 2022, the Centers for Medicare & Medicaid Services (CMS) proposed five new changes to Remote Therapeutic Monitoring (RTM) services under the Medicare program. The changes are part of the proposed 2023 Medicare Physician Fee Schedule rule. To learn more check out this Foley & Lardner article.
On July 7, 2022, the Centers for Medicare and Medicaid Services (CMS) released its proposed 2023 Medicare Physician Fee Schedule (PFS) rule. Learn more about this rule by checking out this article released by Foley and Lardner.
The Centers for Medicare and Medicaid Services (CMS) has announced that it “fully expects” to reverse
Medicare Part B rate cuts for separately payable drugs acquired through the 340B Drug Pricing Program,
resulting in an estimated additional $1.96 billion for 340B hospitals. Learn more through this blog post released by Foley & Lardner.